Mass spectrometry-based AAV protein characterization

Cell & Gene Therapy Insights 2021; 7(10), 1435;

10.18609/cgti.2021.189

Published: 23 November 2021
FastFacts
Andrew Hanneman, PhD


Watch the video or read the poster to learn:

  • How mass spectrometry (MS) supports a wide variety of analytical tests for AAV characterization
  • Intended uses of MS test methods and the information they provide
  • The advantages of incorporating MS detection early in your development program

Andrew Hanneman, PhD currently serves as a scientific advisor for the Biologics division at Charles River Massachusetts. He has over 20 years of experience in the pharmaceutical industry, with a focus on mass spectrometry and glycoprotein characterization. Andrew joined Charles River with the acquisition of Blue Stream Laboratories. He previously served as Associate Director of Mass Spectrometry, overseeing the mass spectrometry laboratory characterizing AAV, mAbs, ADCs, Fc-fusions, enzymes, synthetic peptides, VLPs, and related biomolecules, HCP, and tissue/quantitative proteomics. Andrew received his PhD in wood and natural products chemistry from the University of Washington.